Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

British Journal of Pharmacology

Volumn 166, Issue 1, 2012, Pages 177-193

  May, Richard D ^a   Monk, P D ^b   Cohen, E S ^a   Manuel, D ^a   Dempsey, F ^c   Davis, N H E ^a   Dodd, A J ^a   Corkill, D J ^a   Woods, J ^a   Joberty Candotti, C ^a   Conroy, L A ^a   Koentgen, F ^d   Martin, E C ^e   Wilson, R ^f   Brennan, N ^g   Powell, J ^h   Anderson, I K ^a  

^a MEDIMMUNE   (United States)

^b Synairgen Research Ltd   (United Kingdom)

^c Charles River   (United Kingdom)

^d Ozgene   (Australia)

^e CHARLES RIVER LABORATORIES   (United States)

^f Granary House   (United Kingdom)

^g PanGenetics BV   (United Kingdom)

^h Empanoply   (United Kingdom)

Author keywords

asthma treatment; CAT 354; IgG4; IL 13; preclinical development for asthma; therapeutic antibody; uncontrolled asthma

Indexed keywords

CALCIUM ION; CD23 ANTIGEN; DEXAMETHASONE; IMMUNOGLOBULIN E; INTERLEUKIN 13; TRALOKINUMAB; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; ATOPY; BINDING AFFINITY; BINDING SITE; CALCIUM TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; EOSINOPHIL; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LUNG FIBROBLAST; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ADOLESCENT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION; INTERLEUKIN-13; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; OVALBUMIN; RECEPTORS, IGE; SEVERITY OF ILLNESS INDEX; SPECIES SPECIFICITY; UP-REGULATION;

EID: 84859720060     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01659.x     Document Type: Article

References (56)

1. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME, (2005). Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 35: 1096-1103.
2. Bouteiller CL, Astruc R, Minty A, Ferrara P, Lupker JH, (1995). Isolation of an IL-13-dependent subclone of the B9 cell line useful for the estimation of human IL-13 bioactivity. J Immunol Methods 181: 29-36.
3. Bree A, Schlerman FJ, Wadanoli M, Tchistiakova L, Marquette K, Tan X-Y, et al,. (2007). IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 119: 1251-1257.
4. Chu HW, Trudeau JB, Balzar S, Wenzel S, (2000). Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 106: 1115-1123.
5. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al,. (2010). A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am J Respir Crit Care Med 181: 788-796.
6. Defrance T, Aubry JP, Rousset F, Vanbervliet B, Bonnefoy JY, Arai N, et al,. (1987). Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes. J Exp Med 165: 1459-1467.
7. Deshpande DA, Dogan S, Walseth TF, Miller SM, Amrani Y, Panettieri RA, et al,. (2004). Modulation of calcium signalling by IL-13 in human airway smooth muscle: role of CD38/cADPR pathway. Am J Respir Cell Mol Biol 31: 36-42.
8. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, et al,. (2011). The effects of IL-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 183: 1007-1014.
9. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, et al,. (1998). Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282: 2261-2263.
10. Grunstein MM, Hakonarson H, Leiter J, Chen M, Whelen R, Grunstein JS, et al,. (2002). IL-13 dependent autocrine signalling mediates altered responsiveness of IgE-sensitised airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 282: L520-L528.
11. GINA Guidelines (2010). GINA report, Global strategy for asthma management and prevention.
12. Heinzmann A, Mao XQ, Akaiwa M, Kreomer RT, Gao PS, Ohshima K, et al,. (2000). Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 9: 549-559.
13. Hershey GK, (2003). IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 111: 677-690.
14. Howard TD, Whittaker PA, Zaiman AL, Koppelman GH, Xu J, Hanley MT, et al,. (2001). Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am J Respir Cell Mol Biol 25: 377-384.
15. Howard TD, Koppelman GH, Xu J, Zheng SL, Postma DS, Meyers DA, et al,. (2002). Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 70: 230-236.
16. Huang SK, Xiao HQ, Kleine-Tebbe J, Paciotti G, Marsh DG, Lichtenstein LM, et al,. (1995). IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 155: 2688-2694.
17. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, et al,. (1997). Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 99: 657-665.
18. Jabara HH, Fu SM, Geha RS, Vercelli D, (1990). CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 172: 1861-1864.
19. Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N, et al,. (2008). Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 325: 882-892.
20. Kauppi P, Lindblad-Toh K, Sevon P, Toivonen HT, Rioux JD, Villapakkam A, et al,. (2001). A second-generation association study of the 5q31 cytokine gene cluster and the interleukin-4 receptor in asthma. Genomics 77: 35-42.
21. Kaur D, Hollins F, Woodman L, Yang W, Monk P, May R, et al,. (2006). Mast cells express IL-13Rα1: IL-13 promotes human lung mast cell proliferation and FcεμRI expression. Allergy 61: 1047-1053.
22. Komai-Koma M, McKay A, Thomson L, McSharry C, Chalmers GW, Liew FY, et al,. (2001). Immuno-regulatory cytokines in asthma: IL-15 and IL-13 in induced sputum. Clin Exp Allergy 31: 1441-1448.
23. Kotsimbos TC, Ernst P, Hamid QA, (1996). Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc Assoc Am Phys 108: 368-373.
24. Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W, (1996). Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 9: 899-904.
25. Laporte JC, Moore PE, Baraldo S, Jouvin M, Church TL, Shwartzman IN, et al,. (2001). Direct effects of interleukin-13 on signalling pathways for physiological responses in cultured human airway smooth muscle cells. Am J Respir Crit Care Med 164: 141-148.
26. Liu X, Nickel R, Beyer K, Wahn U, Ehrlich E, Freidhoff LR, et al,. (2000). An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90). J Allergy Clin Immunol 106: 167-170.
27. McKenzie AN, Li X, Largaespada DA, Sato A, Kaneda A, Zurawski SM, et al,. (1993). Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 150: 5436-5444.
28. McMillan SJ, Bishop B, Townsend MJ, McKenzie AN, Lloyd CM, (2002). The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med 195: 51-57.
29. Martin PL, Fisher D, Glass W, O'Neil K, Das A, Martin EC, et al,. (2008). Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma. Int J Toxicol 27: 351-358.
30. Matsukura S, Stellato C, Georas SN, Casolaro V, Plitt JR, Miura K, et al,. (2001). Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol 24: 755-761.
31. Moore PE, Church TL, Chism DD, Panettieri RA Jr, Shore SA, (2002). IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. Am J Physiol Lung Cell Mol Physiol 282: L847-L853.
32. Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME, (2008). Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A 105: 7240-7245.
33. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ, et al,. (1997). Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 155: 845-851.
34. Obase Y, Shimoda T, Mitsuta K, Matsuo N, Matsuse H, Kohno S, (2001). Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. Ann Allergy Asthma Immunol 86: 304-310.
35. Pène J, Rousset F, Brière F, Chrétien I, Bonnefoy JY, Spits H, et al,. (1988). IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S A 85: 6880-6884.
36. Peters SP, Ferguson G, Deniz Y, Reisner C, (2006). Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 100: 1139-1151.
37. van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO, et al,. (1999). An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1: 61-65.
38. Punnonen J, de Vries JE, (1994). IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells. J Immunol 152: 1094-1102.
39. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al,. (1993). Interleukin 13 induces interleukin -4 independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci U S A 90: 3730-3734.
40. Sabroe I, Hartnell A, Jopling LA, Bel S, Ponath PD, Pease JE, et al,. (1999). Differential regulation of eosinophil chemokine signalling via CCR3 and non-CCR3 pathways. J Immunol 162: 2946-2955.
41. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al,. (2008). Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 121: 685-691.
42. Sironi M, Sciacca FL, Matteucci C, Conni M, Vecchi A, Bernasconi S, et al,. (1994). Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood 84: 1913-1921.
43. Skinnider BF, Kapp U, Mak TW, (2001). Interleukin 13: a growth factor in Hodgkin lymphoma. Int Arch Allergy Immunol 126: 267-276.
44. Tamura K, Suzuki M, Arakawa H, Tokuyama K, Morikawa A, (2003). Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int Arch Allergy Immunol 131: 33-38.
45. Terada N, Hamano N, Nomura T, Numata T, Hirai K, Nakajima T, et al,. (2000). Interleukin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy 30: 348-355.
46. Thom G, Cockroft AC, Buchanan AG, Candotti CJ, Cohen ES, Lowne D, et al,. (2006). Probing a protein-protein interaction by in vitro evolution. Proc Natl Acad Sci U S A 103: 7619-7624.
47. Tliba O, Deshpande D, Chen H, van Beisien C, Kannan M, Panettieri RA, et al,. (2003). IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol 140: 1159-1162.
48. Turner CR, Andresen CJ, Smith WB, Watson JW, (1996). Characterization of a primate model of asthma using anti-allergy/anti-asthma agents. Inflamm Res 45: 239-245.
49. Vladich FD, Brazille SM, Stern D, Peck ML, Ghittoni R, Vercelli D, (2005). IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J Clin Invest 115: 747-754.
50. Wakeland E, Morel L, Achey K, Yui M, Longmate J, (1997). Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today 10: 472-477.
51. Webb DC, McKenzie ANJ, Koskinen AML, Yang M, Mattes J, Foster PS, (2000). Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 165: 108-113.
52. Wenzel SE, Trudeau JB, Barnes S, Zhou X, Cundall M, Wescott J, et al,. (2002). TGF-β and IL-13 synergistivally increase eotaxin-1 production in human airway fibroblasts. J Immunol 169: 4613-4619.
53. Wenzel S, Wilbraham D, Fuller R, Burmeister Getz E, Longphre M, (2007). Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370: 1422-1431.
54. Wenzel SE, Ind PW, Otulana BA, Bleecker ER, Kuna P, Yen YP, (2010). Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. P3980, 714s, European Respiratory Society 2010 Meeting.
55. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al,. (1998). Interleukin-13: central mediator of allergic asthma. Science 282: 2258-2261.
56. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al,. (1999). Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103: 779-788.